The popular diabetes drug rosiglitazone, marketed as Avandia, more than doubles the long-term risk of heart failure and increases the long-term risk of heart attack by 42 percent, according to a new analysis.
Rosiglitazone initially came under scrutiny earlier this year when an analysis of short-term trials found a 43 percent increase in risk of heart attack among people taking the drug (SN: 6/23/07, p. 397). The Food and Drug Administration called an emergency advisory committee meeting, and in July that group agreed that the drug increases the risk of heart attack. However, the panel recommended that the FDA keep rosiglitazone on the market. The agency is now reviewing data and weighing options on the drug.
Note: To comment, Science News subscribing members must now establish a separate login relationship with Disqus. Click the Disqus icon below, enter your e-mail and click “forgot password” to reset your password. You may also log into Disqus using Facebook, Twitter or Google.